Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for glucose tolerance in antipsychotic-treated psychiatric patients
2013-000121-31Phase 2Completed
- Sponsor
- Prof., dr. med. Anders Fink-Jensen
- Start
- Mar 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of liraglutide in prediabetes and Glycemic dysregulation (2 arms), sponsored by Prof., dr. med. Anders Fink-Jensen. Primary endpoint: Change in glucose tolerance. Started Mar 2013; status: completed.
02
Drugs
03
Conditions
prediabetesGlycemic dysregulation
Beyond the preview
Go deeper on 2013-000121-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000121-31.